Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Study ID
NCT03134118
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Thymic Carcinoma
  • Thymoma Type B3

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks

Study Details

The aim of the phase II Nivothym study is to collect data on activity and toxicity of nivolumab therapy in patients with thymic carcinoma or type B3 thymoma that previously received a first platinum-based chemotherapy.

Key Dates

Start date
Apr 11, 2018
Status verified
May 2026
Primary completion
Sep 5, 2023
Completion
Dec 31, 2027

Study Design

Enrollment
55 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nivolumab
    Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks

Primary Outcome Measure

Progression Free Survival Rate (PFSR) at month 6 [ Time Frame: The Progression Free Survival Rate (PFSR) analysis will be performed at month 6 ]

Related Studies